Nanion Corporate Blog


14.10.2021: Meet Us - ELRIG Drug Discovery 2021

Conference Venue:
Location: Kings Dock St, Liverpool, Merseyside
Country: United Kingdom

Go to the Conference website here

Meet Dr. Alison Obergrussberger (Nanion Technologies GmbH) as she will present the following poster:

Poster #9: Reliable identification of cardiac liability in drug discovery using automated patch clamp: Experimental and technical considerations for high throughput recordings of NaV1.5 and hERG

The aim of the CiPA initiative is to improve specificity compared to in vitro hERG and in vivo QT studies. Automated patch clamp (APC) instruments are increasingly adopted for cardiac safety measurements on hERG, NaV1.5 and CaV1.2, thus requiring standardized experimental protocols and technical specifications, e.g. temperature control, accessibility of recording solutions to allow for sample collection or Liquid Junction Potential (LJP) correction for accurate voltage control. Here, we identified parameters influencing IC50 determination of compounds on hERG and NaV1.5 currents recorded using APC. For example, we found that although voltage protocol did not affect the IC50 of hERG compounds, both voltage protocol and holding potential could affect IC50 on NaV1.5 peak currents. Compounds ranolazine and tamoxifen, two blockers known to block NaV1.5 in the open state, showed more potent IC50s at a holding potential (HP) of -80 mV compared with -95 mV. Temperature could also influence IC50 values of compounds tested on NaV1.5 peak. Temperature affected the Vhalf of inactivation, shifting Vhalf of inactivation by ~7 mV to more negative potentials at 37°C vs room temperature (RT), and also affected the IC50 of mexiletine. Given the influence of temperature on NaV1.5 and hERG biophysics and pharmacology, it is critical to maintain a constant recording temperature of the system either by cooling where room temperature fluctuates, or heating to record at physiological temperature. Experimental parameters such as incubation time also influenced IC50 values for both hERG and NaV1.5 peak currents and whereas compounds such as bepridil reached steady state within approximately 5-6 mins, sticky compounds such as terfenadine required longer incubation times. In keeping with this, the open-well design of the patch clamp chip makes it possible to collect samples directly from the measurement site. This allows the direct measurement of actual compound concentration at the cell.

The poster session will held on October 19th, 2021 (Tuesday) between 5 PM - 7 PM BST 

Schedule a meeting with me

Additional Readings

Journal of Pharmacological and Toxicological Methods - Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment

Journal of Pharmacological and Toxicological Methods - Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening environment

The Journal of Physiology - The suitability of high throughput automated patch clamp for physiological applications

Back to Overview


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.